A Phase 3 interventional study of Pitavastatin and Simvastatin in Hypercholesterolemia and Dyslipidemia, sponsored by Kowa Research Europe. Completed at 42 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2010-01-12.
Sponsored by Kowa Research Europe (part of Kowa Company, Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing pitavastatin in Hypercholesterolemia — none open to participants now, none under way, none of them phase 3. pitavastatin · Hypercholesterolemia.
Among the 19 studies testing pitavastatin in Hypercholesterolemia, this one is the 3rd largest by enrollment, is one of 5 that started in 2005, is one of 9 in phase 3, and was the 3rd registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →None of the 19 studies testing pitavastatin in Hypercholesterolemia is open now. The open studies under Hypercholesterolemia, anywhere →
pitavastatin: first FDA approval 2009 (LIVALO). What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 5 started in 2005.
This study's enrollment of 857 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 200 across the 19 interventional studies. Of the 19 that completed or were terminated, 11 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 19 have an industry lead sponsor. The 10 most frequent:
This study is registered under Kowa Research Europe, one of the names counted as Kowa Company, Ltd.. Under that name alone:
Kowa Research Europe is the lead sponsor of 10 studies on the registry; none are open to participants now.
11 studies in Hypercholesterolemia by Kowa Company, Ltd.: 1 open now, 1 under way, none of them phase 3. Of 10 finished, 7 (70%) have results posted.
Among the 11 studies in Hypercholesterolemia by Kowa Company, Ltd., this one is the 3rd largest by enrollment, is one of 4 that started in 2005, is one of 10 in phase 3, and was the 2nd registered.
Kowa Company, Ltd.’s Hypercholesterolemia studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing pitavastatin in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Kowa Company, Ltd.’s 11 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the efficacy and safety of pitavastatin with that of simvastatin.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pitavastatin 2 mg once daily
Drug: Pitavastatin
Simvastatin 20 mg once daily
Drug: Simvastatin
Pitavastatin 4 mg once daily
Drug: Pitavastatin
Simvastatn 40 mg once daily
Drug: Simvastatin
Pitavastatin once daily
Simvastatin once daily
Percent Change From Baseline in Low Density Lipoprotein-cholesterol (LDL-C) at 12 Weeks
Percent change from baseline in low density lipoprotein-cholesterol (LDL-C)after 12 Weeks
Time frame: Baseline to 12 weeks
National Cholesterol Education Program (NCEP) LDL-C Target Attainment
Number of subjects achieving National Cholesterol Education Program (NCEP) LDL-C Target (LDL less than or equal to 130 mg/dL)at Week 12
Time frame: 12 week
Subjects were randomized to one of 4 treatment arms based on inclusion/exclusion criteria.
| Milestone | Pitavastatin 2 mg | Simvastatin 20 mg | Pitavastatin 4 mg | Simvastatin 40 mg |
|---|---|---|---|---|
| Started | 315 | 108 | 323 | 111 |
| Safety population | 311 | 107 | 320 | 110 |
| Completed | 292 | 99 | 304 | 107 |
| Not completed | 23 | 9 | 19 | 4 |
| Withdrew: Adverse event | 13 | 2 | 8 | 1 |
| Withdrew: Protocol violation | 4 | 1 | 3 | 1 |
| Withdrew: Withdrawal by subject | 6 | 5 | 7 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 |
| Withdrew: Death | 0 | 1 | 0 | 0 |
Percent change from baseline in low density lipoprotein-cholesterol (LDL-C)after 12 Weeks
| Percent change | Pitavastatin 2 mg | Simvastatin 20 mg | Pitavastatin 4 mg | Simvastatin 40 mg |
|---|---|---|---|---|
| Percent Change From Baseline in Low Density Lipoprotein-cholesterol (LDL-C) at 12 Weeks | -38.99 ± 14.573 | -34.97 ± 15.528 | -43.97 ± 14.494 | -42.84 ± 15.769 |
Number of subjects achieving National Cholesterol Education Program (NCEP) LDL-C Target (LDL less than or equal to 130 mg/dL)at Week 12
| Participants | Pitavastatin 2 mg | Simvastatin 20 mg | Pitavastatin 4 mg | Simvastatin 40 mg |
|---|---|---|---|---|
| National Cholesterol Education Program (NCEP) LDL-C Target Attainment | 215 | 69 | 253 | 86 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pitavastatin 2 mg | — | 3/311 (1%) | 56/311 (18%) |
| Simvastatin 20 mg | — | 2/107 (1.9%) | 28/107 (26.2%) |
| Pitavastatin 4 mg | — | 4/320 (1.3%) | 44/320 (13.8%) |
| Simvastatin 40 mg | — | 2/110 (1.8%) | 10/110 (9.1%) |
| Event | Pitavastatin 2 mg | Simvastatin 20 mg | Pitavastatin 4 mg | Simvastatin 40 mg |
|---|---|---|---|---|
| ErysipelasInfections and infestations | 0/311 | 0/107 | 0/320 | 2/110 |
| Atrial fibrillationCardiac disorders | 0/311 | 1/107 | 0/320 | 0/110 |
| Sudden cardiac deathGeneral disorders | 0/311 | 1/107 | 0/320 | 0/110 |
| PleuropericarditisCardiac disorders | 1/311 | 0/107 | 0/320 | 0/110 |
| Pancreatitis acuteGastrointestinal disorders | 1/311 | 0/107 | 0/320 | 0/110 |
| Anaphylactic reationImmune system disorders | 1/311 | 0/107 | 0/320 | 0/110 |
| Non-cardiac chest painGeneral disorders | 0/311 | 0/107 | 1/320 | 0/110 |
| Campylobacter intestinal infectionInfections and infestations | 0/311 | 0/107 | 1/320 | 0/110 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/311 | 0/107 | 1/320 | 0/110 |
| ConvulsionNervous system disorders | 0/311 | 0/107 | 1/320 | 0/110 |
| Event | Pitavastatin 2 mg | Simvastatin 20 mg | Pitavastatin 4 mg | Simvastatin 40 mg |
|---|---|---|---|---|
| InfluenzaInfections and infestations | 4/311 | 6/107 | 1/320 | 1/110 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 4/311 | 5/107 | 3/320 | 0/110 |
| HeadacheNervous system disorders | 10/311 | 4/107 | 11/320 | 2/110 |
| MyalgiaMusculoskeletal and connective tissue disorders | 9/311 | 3/107 | 6/320 | 3/110 |
| Back painMusculoskeletal and connective tissue disorders | 3/311 | 3/107 | 7/320 | 1/110 |
| NauseaGastrointestinal disorders | 4/311 | 3/107 | 6/320 | 1/110 |
| DiarrheaGastrointestinal disorders | 8/311 | 2/107 | 6/320 | 1/110 |
| Upper respiratory tract infectionInfections and infestations | 7/311 | 1/107 | 3/320 | 1/110 |
| FatigueGeneral disorders | 7/311 | 1/107 | 1/320 | 0/110 |
| Age, Categorical(Participants) | Pitavastatin 2 mg | Simvastatin 20 mg | Pitavastatin 4 mg | Simvastatin 40 mg | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 214 | 72 | 231 | 76 | 593 |
| >=65 years | 97 | 35 | 89 | 34 | 255 |
| Age Continuous(years) | Pitavastatin 2 mg | Simvastatin 20 mg | Pitavastatin 4 mg | Simvastatin 40 mg | Total |
|---|---|---|---|---|---|
| Mean | 58.7 ± 8.83 | 58.6 ± 9.64 | 57.7 ± 8.97 | 58.4 ± 9.54 | 58.3 ± 9.08 |
| Sex: Female, Male(Participants) | Pitavastatin 2 mg | Simvastatin 20 mg | Pitavastatin 4 mg | Simvastatin 40 mg | Total |
|---|---|---|---|---|---|
| Female | 196 | 63 | 195 | 48 | 502 |
| Male | 115 | 44 | 125 | 62 | 346 |
The record gives a start of Sep 2005, a primary completion of Oct 2006 and a completion of Oct 2006. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2009, 3 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pitavastatin